VAX014

About Vaxiion Therapeutics

Vaxiion Therapeutics, founded in 2016 and based in San Diego, is advancing a novel, non-viral immunotherapy platform centered on engineered bacterial minicells. Its lead candidate, VAX014, is a first-in-class, tumor-targeted oncolytic immunotherapy currently in early-stage clinical trials for advanced solid tumors and non-muscle invasive bladder cancer. The company positions itself at the intersection of personalized medicine and immunotherapy, aiming to develop safer, more effective treatments for cancers resistant to standard therapies. With a focus on translating its proprietary science into patient outcomes, Vaxiion is a private, pre-revenue biotech building a pipeline of targeted immunotherapies.

About Vaxiion Therapeutics

Vaxiion Therapeutics, founded in 2016 and based in San Diego, is advancing a novel, non-viral immunotherapy platform centered on engineered bacterial minicells. Its lead candidate, VAX014, is a first-in-class, tumor-targeted oncolytic immunotherapy currently in early-stage clinical trials for advanced solid tumors and non-muscle invasive bladder cancer. The company positions itself at the intersection of personalized medicine and immunotherapy, aiming to develop safer, more effective treatments for cancers resistant to standard therapies. With a focus on translating its proprietary science into patient outcomes, Vaxiion is a private, pre-revenue biotech building a pipeline of targeted immunotherapies.

Therapeutic Areas